查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1802942

2032 年端粒基因治療市場預測：按治療類型、給藥方式、發展階段、載體類型、疾病適應症、應用、最終用戶和地區進行的全球分析

Telomere Gene Therapy Market Forecasts to 2032 - Global Analysis By Therapy Type, Delivery Method, Development Stage, Vector Type, Disease Indication, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球端粒基因治療市場預計在 2025 年價值 6,075 萬美元，預計到 2032 年將達到 2.3745 億美元，預測期內的複合年成長率為 21.5%。

端粒基因療法是再生醫學的新興領域，致力於延長或恢復端粒——染色體末端的保護帽，它會隨著細胞分裂和衰老而縮短。細胞老化、老齡化和老齡化相關疾病都與端粒縮短密切相關。透過利用基因治療技術活化端粒酶（一種保存和延長端粒的酶），科學家希望能夠使細胞恢復活力，增強組織功能，並可能推遲退化性疾病的發生。雖然安全性問題（包括不受控制的細胞增殖和致癌可能性）仍然是主要障礙，但早期在動物模型上的研究已顯示出令人鼓舞的結果，包括壽命和健康壽命的延長。

《歐洲分子醫學組織》（EMBO Molecular Medicine）發表的一項研究發現，端粒酶基因治療使小鼠的平均壽命延長了24%，且癌症發生率沒有增加。接受治療的小鼠也表現出組織再生能力增強，老化標記減少。

遺傳和老齡化相關疾病的發生率不斷上升

推動端粒基因治療市場發展的主要因素之一是與老齡化相關的遺傳性疾病的日益增多。端粒縮短與阿茲海默症和心血管疾病等退化性疾病一樣，也是特發性肺纖維化、再次障礙性貧血和骨髓發育不良症候群等疾病的關鍵因素。隨著人口老化，針對細胞衰退根本原因的治療需求顯著增加。早期診斷、生物標記識別和基因檢測的進展也增加了符合創新療法條件的患者數量。此外，隨著全球慢性病發病率的上升，以端粒為重點的干涉措施被視為減緩疾病進展和改善生活品質的一種頗具吸引力的選擇。

增加罹癌的風險

端粒基因治療發展面臨的最大障礙之一是細胞增殖失控的風險增加，可能導致癌症。由於大多數成年體細胞會自然抑制端粒酶活性，人工重新重新運作該活性可能會促進惡性轉化。臨床應用必須嚴格控制，以防止癌前細胞永生化。這種風險會增加監管審查，使治療設計複雜化，並延緩開發進度。安全性問題，尤其是在抗衰老和預防應用方面，限制了患者的接受度，並引發了倫理爭議。因此，致癌性仍然是阻礙端粒療法廣泛應用的最大生物學和經濟障礙。

長壽醫學和抗衰老醫學的成長

長壽和抗衰老齡化醫學領域的快速發展為端粒基因療法提供了最光明的前景之一。老化的主要徵兆之一是端粒縮短，而延長端粒的治療可以延長壽命，甚至延緩與老齡化相關的衰老。隨著世界各地人們壽命的延長，對不僅能治療疾病還能保持活力的解決方案的需求也日益成長。透過吸引健康產業、私人長壽診所和消費者導向的生技公司，端粒療法有望從疾病管理擴展到預防性醫療保健。

來自替代醫學的競爭

來自替代療法的競爭，例如幹細胞療法、抗衰老藥物、基於CRISPR的基因組編輯以及改變mTOR、NAD+和sirtuins等衰老通路的小分子藥物，對端粒基因治療構成了重大威脅。與基於端粒的干涉措施相比，這些治療方法的製造成本更低、安全隱患更少，並且經常通過臨床試驗。如果這些競爭技術被證明能夠成功治療退化性疾病或延長壽命，端粒療法可能很難出現。儘管端粒療法具有生物學潛力，但投資者和醫療保健提供者可能更傾向於更安全、更成熟的替代技術。

COVID-19的影響：

端粒基因治療市場在許多方面受到了 COVID-19 疫情的影響。一方面，全球資金籌措週期、供應鏈和臨床試驗的中斷暫時減緩了研究進度，並推遲了幾種實驗性治療方法的開發時間表。然而，疫情也增加了人們對基於基因的解決方案的興趣，因為病毒載體平台和 mRNA 疫苗迅速證明了其擴充性和安全性。先進的遞送系統的檢驗增強了對基因介入的投資和監管信心，間接使端粒相關研究受益。此外，鑑於 COVID-19 的長期健康影響，例如某些患者的免疫功能障礙和生物老化加速，端粒標靶治療至關重要。

端粒酶活化療法預計將成為預測期內最大的治療領域

端粒酶激活療法預計將在預測期內佔據最大的市場佔有率，因為其主要目標是改善或重新運作端粒酶——一種維持和延長端粒的酶。此策略透過逆轉端粒縮短直接解決了細胞老化的基本過程之一，使其在治療和預防方面都極具吸引力。臨床研究和營養補充劑（例如端粒酶活化劑）已證明對端粒長度和免疫功能具有可量化的影響，進一步激發了人們的興趣。端粒酶活化療法是市場上商業性程度最高、科學檢驗最充分的領域，其發展受到長壽醫學、抗衰老研究和再生醫療領域強勁需求的推動。

腺結合病毒(AAV) 部分預計將在預測期內實現最高複合年成長率

腺結合病毒(AAV) 領域預計將在預測期內呈現最高成長率。這得益於其良好的安全記錄、能夠長時間產生基因表現以及引發免疫反應的風險相對較低。許多人認為 AAV 載體是遞送遺傳物質最可靠的方法，尤其適用於需要長期療效的老齡化性疾病和慢性疾病的治療。 AAV 載體核准罕見疾病基因治療的成功，進一步增強了人們對使用 AAV 載體進行端粒干預的信心。

比最大的地區

預計北美將在預測期內佔據最大的市場佔有率。該地區擁有強大的生物技術部門、先進的醫療保健系統以及對基因和抗衰老研究的大量投資。由於大量的臨床試驗、已建立的監管途徑（如 FDA RMAT 指定）以及處於端粒療法前沿的關鍵生物技術公司和新興企業的存在，美國在該領域處於全球市場領先地位。大量創業投資資金籌措、產學合作以及最尖端科技的早期採用進一步加強了該地區的主導地位。此外，由於對癌症和與老齡化相關的疾病的最先進治療療法的需求不斷成長，北美將繼續在全球佔據最大市場佔有率。

複合年成長率最高的地區：

受人口老化、醫療成本上漲以及政府對生物技術研究的大力資助推動，預計亞太地區在預測期內將呈現最高的複合年成長率。再生醫學和基因療法正吸引來自中國、日本和韓國等國的大量投資。國內生物技術公司與國際公司之間的臨床試驗和合作也不斷增加。隨著醫療基礎設施的改善和人們對長壽科學認知的不斷提高，端粒相關創新的有利環境正在形成。此外，亞太地區經濟高效的生產能力和令人鼓舞的監管變化也加速了相關技術的採用，使亞太地區成為成長最快的市場領域。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球端粒基因治療市場（依治療類型）

  • 端粒酶活化治療
  • 端粒延長療法
  • 端粒保護療法

6. 全球端粒基因治療市場（以遞送方式）

  • 病毒載體
  • 非病毒方法
  • 體外受精
  • 體內遞送

7. 全球端粒基因治療市場（依發展階段）

  • 臨床前
  • 臨床試驗（I期）
  • 臨床試驗（II期）
  • 臨床試驗（III期）
  • 核准的治療方法
  • 管道候選人

8. 全球端粒基因治療市場（依載體型）

  • 腺結合病毒（AAV）
  • 慢病毒
  • 逆轉錄病毒
  • 腺病毒
  • 其他向量類型

9. 全球端粒基因治療市場（依疾病適應症）

  • 特發性肺纖維化
  • 再生障礙性貧血
  • 癌症亞型
  • 罕見端粒疾病

第 10 章全球端粒基因治療市場（按應用）

  • 抗老和長壽
  • 腫瘤學
  • 遺傳性疾病
  • 再生醫學

第 11 章全球端粒基因治療市場（按最終用戶）

  • 醫院和診所
  • 研究與機構
  • 生物技術和製藥公司

12. 全球端粒基因治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第13章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第14章 公司概況

  • Geron Corporation
  • AgeX Therapeutics
  • Turn Biotechnologies
  • Calico Life Sciences
  • Juvenescence Ltd
  • Sierra Sciences
  • Telomere Therapeutics
  • Altos Labs Inc
  • BioViva Sciences
  • Retro Biosciences
  • Telocyte
  • Elixirgen Therapeutics
Product Code: SMRC30468

According to Stratistics MRC, the Global Telomere Gene Therapy Market is accounted for $60.75 million in 2025 and is expected to reach $237.45 million by 2032 growing at a CAGR of 21.5% during the forecast period. Telomere gene therapy is an emerging field of regenerative medicine that focuses on extending or restoring telomeres-the protective caps at the ends of chromosomes that shorten as cells divide and age. Cellular senescence, aging, and age-related disorders are all strongly associated with telomere shortening. Scientists hope to revitalize cells, enhance tissue function, and possibly postpone the onset of degenerative diseases by employing gene therapy techniques to activate telomerase, the enzyme that preserves and lengthens telomeres. Although safety issues, such as the possibility of unchecked cell growth and cancer, continue to be significant obstacles, early research in animal models has produced encouraging results, such as an extended lifespan and health span.

According to a study published in EMBO Molecular Medicine, data shows that telomerase gene therapy in mice extended their median lifespan by 24% without increasing cancer incidence. Treated mice showed improved tissue regeneration and reduced markers of aging.

Market Dynamics:

Driver:

Increasing frequencies of genetic and age-related disorders

One of the main factors propelling the telomere gene therapy market is the growing prevalence of age-related and genetic illnesses. Along with degenerative diseases like Alzheimer's and cardiovascular disease, telomere shortening is a key factor in diseases likes idiopathic pulmonary fibrosis, aplastic anemia, and myelodysplastic syndromes. The need for treatments that target the underlying causes of cellular decline rises significantly as populations age. The number of patients eligible for innovative treatments is also growing as a result of advancements in early diagnostics, biomarker identification, and genetic testing. Additionally, telomere-focused interventions are positioned as appealing choices to slow disease progression and enhance quality of life as the incidence of chronic diseases rises worldwide.

Restraint:

Elevated oncogenesis risk

The increased risk of causing unchecked cell growth, which can result in cancer, is one of the most significant barriers to the development of telomere gene therapy. The majority of adult somatic cells naturally suppress telomerase activity, so reactivating it artificially runs the risk of facilitating malignant transformation. To prevent precancerous cells from becoming immortal, clinical translation needs to be carefully controlled. This risk slows development timelines by increasing regulatory scrutiny and complicating therapy design. Safety issues restrict patient acceptance and spark ethical discussions, especially when it comes to anti-aging or preventive applications. As a result, the biggest biological and financial obstacle to the widespread use of telomere therapy is still oncogenesis.

Opportunity:

Growth into longevity and anti-aging medicine

The quickly expanding fields of longevity and anti-aging medicine present one of the most promising prospects for telomere gene therapy. One of the main signs of aging is telomere shortening; treatments that lengthen telomeres may prolong life and even postpone age-related decline. The demand for solutions that not only treat illness but also maintain vitality is rising as people around the world live longer. By attracting wellness sectors, private longevity clinics, and consumer-focused biotech companies, telomere therapy may expand beyond disease management into preventive healthcare.

Threat:

Competition from alternative medical practices

The competition from alternative therapeutic approaches, such as stem cell therapy, senolytics, CRISPR-based genome editing, and small-molecule medications that alter aging pathways like mTOR, NAD+, or sirtuins, is a significant threat to telomere gene therapy. Compared to telomere-based interventions, these therapies may be less expensive to produce, have fewer safety concerns, and are frequently more advanced in clinical trials. Telomere therapies might find it difficult to stand out if these rival technologies are successful in treating degenerative diseases or prolonging life expectancy. Despite telomere therapy's biological potential, investors and healthcare providers may favor safer, more thoroughly proven alternatives, which would slow adoption and confine it to a specialized role.

Covid-19 Impact:

The market for telomere gene therapy experienced mixed effects from the COVID-19 pandemic. On the one hand, worldwide disruptions in funding cycles, supply chains, and clinical trials momentarily slowed down research, causing several experimental therapies' development timelines to be delayed. However, the pandemic also increased interest in gene-based solutions because viral vector platforms and mRNA vaccines quickly demonstrated their scalability and safety. The validation of sophisticated delivery systems increased investment and regulatory confidence in genetic interventions, which indirectly benefited telomere-focused research. Moreover, telomere-targeted treatments are also important because of the long-term health effects of COVID-19, which include immunological dysfunction and accelerated biological aging in certain patients.

The telomerase activation therapy segment is expected to be the largest during the forecast period

The telomerase activation therapy segment is expected to account for the largest market share during the forecast period because its main goal is to improve or reactivate telomerase, the enzyme that keeps and lengthens telomeres. This strategy directly addresses one of the fundamental processes of cellular aging by reversing telomere shortening, which makes it very appealing for both therapeutic and preventive uses. Interest has been further stoked by clinical research and nutraceutical products that demonstrate quantifiable effects on telomere length and immune function, such as telomerase activators. As the most commercially advanced and scientifically validated segment of the market, telomerase activation therapy leads due to strong demand from longevity medicine, anti-aging research, and regenerative healthcare.

The adeno-associated virus (AAV) segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the adeno-associated virus (AAV) segment is predicted to witness the highest growth rate, motivated by its good safety record, capacity to produce gene expression over an extended period of time, and comparatively low risk of inciting immunological reactions. Many people believe that AAV vectors are the most dependable way to deliver genetic material, particularly in treatments for age-related and chronic illnesses where long-lasting effects are needed. Confidence in their application for telomere-based interventions has been further increased by their demonstrated success in approved gene therapies for rare diseases.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, bolstered by its robust biotechnology sector, sophisticated healthcare system, and substantial investment in genetic and anti-aging research. With a large number of clinical trials, well-established regulatory pathways such as the FDA's RMAT designation, and the presence of significant biotech companies and startups at the forefront of telomere-focused therapies, the United States leads the world in this area. The region's dominance is further strengthened by substantial venture capital funding, industry-academia partnerships, and early adoption of cutting-edge technologies. Furthermore, North America continues to hold the biggest market share in the world due to rising demand for cutting-edge treatments that target cancer and age-related illnesses.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, propelled by its aging population, growing healthcare costs, and robust government funding for biotechnology research. Regenerative medicine and gene therapy are receiving significant investments from nations like China, Japan, and South Korea. There are also more clinical trials and collaborations between domestic biotech companies and international players. An environment that is conducive to telomere-based innovations is being created by the growing healthcare infrastructure and increased awareness of longevity science. Moreover, the region's cost-effective manufacturing capabilities and encouraging regulatory changes are also speeding up adoption, making Asia-Pacific the market segment with the fastest rate of growth.

Key players in the market

Some of the key players in Telomere Gene Therapy Market include Geron Corporation, AgeX Therapeutics, Turn Biotechnologies, Calico Life Sciences, Juvenescence Ltd, Sierra Sciences, Telomere Therapeutics, Altos Labs Inc, BioViva Sciences, Retro Biosciences, Telocyte and Elixirgen Therapeutics.

Key Developments:

In June 2025, Calico Life Sciences has struck an exclusive licensing agreement with Chinese drugmaker Mabwell for investigational therapies aimed at interleukin-11 (IL-11), including a Phase I-stage monoclonal antibody targeting age-related conditions. Under the deal, Calico is paying $25 million upfront to gain global rights-excluding greater China-to 9MW3811, the lead IL-11 candidate. The agreement could eventually reach $571 million, tied to development and commercial milestones.

In November 2024, Geron Corporation has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo. The money, which will also be used to advance the firm's pipeline, comprises $250 million in debt from funds managed by Pharmakon Advisors and a $125 million synthetic royalty agreement with Royalty Pharma.

In May 2024, Turn Biotechnologies announced an exclusive global licensing agreement with pharmaceutical manufacturer HanAll Biopharma to develop groundbreaking medicines for the treatment of age-related eye and ear conditions. The agreement, potentially exceeding $300 million in value for the first of multiple planned products, significantly expands the relationship between the companies. HanAll originally invested in Turn Bio in 2022.

Therapy Types Covered:

  • Telomerase Activation Therapy
  • Telomere Lengthening Therapy
  • Telomere Protection Therapy

Delivery Methods Covered:

  • Viral Vectors
  • Non-Viral Methods
  • Ex Vivo Delivery
  • In Vivo Delivery

Development Stages Covered:

  • Preclinical
  • Clinical Trials (Phase I)
  • Clinical Trials (Phase II)
  • Clinical Trials (Phase III)
  • Approved Therapies
  • Pipeline Candidates

Vector Types Covered:

  • Adeno-Associated Virus (AAV)
  • Lentivirus
  • Retrovirus
  • Adenovirus
  • Other Vector Types

Disease Indications Covered:

  • Idiopathic Pulmonary Fibrosis
  • Aplastic Anemia
  • Cancer Subtypes
  • Rare Telomere Disorders

Applications Covered:

  • Anti-Aging & Longevity
  • Oncology
  • Genetic Disorders
  • Regenerative Medicine

End Users Covered:

  • Hospitals & Clinics
  • Research Institutes
  • Biotech & Pharmaceutical Companies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Telomere Gene Therapy Market, By Therapy Type

  • 5.1 Introduction
  • 5.2 Telomerase Activation Therapy
  • 5.3 Telomere Lengthening Therapy
  • 5.4 Telomere Protection Therapy

6 Global Telomere Gene Therapy Market, By Delivery Method

  • 6.1 Introduction
  • 6.2 Viral Vectors
  • 6.3 Non-Viral Methods
  • 6.4 Ex Vivo Delivery
  • 6.5 In Vivo Delivery

7 Global Telomere Gene Therapy Market, By Development Stage

  • 7.1 Introduction
  • 7.2 Preclinical
  • 7.3 Clinical Trials (Phase I)
  • 7.4 Clinical Trials (Phase II)
  • 7.5 Clinical Trials (Phase III)
  • 7.6 Approved Therapies
  • 7.7 Pipeline Candidates

8 Global Telomere Gene Therapy Market, By Vector Type

  • 8.1 Introduction
  • 8.2 Adeno-Associated Virus (AAV)
  • 8.3 Lentivirus
  • 8.4 Retrovirus
  • 8.5 Adenovirus
  • 8.6 Other Vector Types

9 Global Telomere Gene Therapy Market, By Disease Indication

  • 9.1 Introduction
  • 9.2 Idiopathic Pulmonary Fibrosis
  • 9.3 Aplastic Anemia
  • 9.4 Cancer Subtypes
  • 9.5 Rare Telomere Disorders

10 Global Telomere Gene Therapy Market, By Application

  • 10.1 Introduction
  • 10.2 Anti-Aging & Longevity
  • 10.3 Oncology
  • 10.4 Genetic Disorders
  • 10.5 Regenerative Medicine

11 Global Telomere Gene Therapy Market, By End User

  • 11.1 Introduction
  • 11.2 Hospitals & Clinics
  • 11.3 Research Institutes
  • 11.4 Biotech & Pharmaceutical Companies

12 Global Telomere Gene Therapy Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Geron Corporation
  • 14.2 AgeX Therapeutics
  • 14.3 Turn Biotechnologies
  • 14.4 Calico Life Sciences
  • 14.5 Juvenescence Ltd
  • 14.6 Sierra Sciences
  • 14.7 Telomere Therapeutics
  • 14.8 Altos Labs Inc
  • 14.9 BioViva Sciences
  • 14.10 Retro Biosciences
  • 14.11 Telocyte
  • 14.12 Elixirgen Therapeutics

List of Tables

  • Table 1 Global Telomere Gene Therapy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Telomere Gene Therapy Market Outlook, By Therapy Type (2024-2032) ($MN)
  • Table 3 Global Telomere Gene Therapy Market Outlook, By Telomerase Activation Therapy (2024-2032) ($MN)
  • Table 4 Global Telomere Gene Therapy Market Outlook, By Telomere Lengthening Therapy (2024-2032) ($MN)
  • Table 5 Global Telomere Gene Therapy Market Outlook, By Telomere Protection Therapy (2024-2032) ($MN)
  • Table 6 Global Telomere Gene Therapy Market Outlook, By Delivery Method (2024-2032) ($MN)
  • Table 7 Global Telomere Gene Therapy Market Outlook, By Viral Vectors (2024-2032) ($MN)
  • Table 8 Global Telomere Gene Therapy Market Outlook, By Non-Viral Methods (2024-2032) ($MN)
  • Table 9 Global Telomere Gene Therapy Market Outlook, By Ex Vivo Delivery (2024-2032) ($MN)
  • Table 10 Global Telomere Gene Therapy Market Outlook, By In Vivo Delivery (2024-2032) ($MN)
  • Table 11 Global Telomere Gene Therapy Market Outlook, By Development Stage (2024-2032) ($MN)
  • Table 12 Global Telomere Gene Therapy Market Outlook, By Preclinical (2024-2032) ($MN)
  • Table 13 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase I) (2024-2032) ($MN)
  • Table 14 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase II) (2024-2032) ($MN)
  • Table 15 Global Telomere Gene Therapy Market Outlook, By Clinical Trials (Phase III) (2024-2032) ($MN)
  • Table 16 Global Telomere Gene Therapy Market Outlook, By Approved Therapies (2024-2032) ($MN)
  • Table 17 Global Telomere Gene Therapy Market Outlook, By Pipeline Candidates (2024-2032) ($MN)
  • Table 18 Global Telomere Gene Therapy Market Outlook, By Vector Type (2024-2032) ($MN)
  • Table 19 Global Telomere Gene Therapy Market Outlook, By Adeno-Associated Virus (AAV) (2024-2032) ($MN)
  • Table 20 Global Telomere Gene Therapy Market Outlook, By Lentivirus (2024-2032) ($MN)
  • Table 21 Global Telomere Gene Therapy Market Outlook, By Retrovirus (2024-2032) ($MN)
  • Table 22 Global Telomere Gene Therapy Market Outlook, By Adenovirus (2024-2032) ($MN)
  • Table 23 Global Telomere Gene Therapy Market Outlook, By Other Vector Types (2024-2032) ($MN)
  • Table 24 Global Telomere Gene Therapy Market Outlook, By Disease Indication (2024-2032) ($MN)
  • Table 25 Global Telomere Gene Therapy Market Outlook, By Idiopathic Pulmonary Fibrosis (2024-2032) ($MN)
  • Table 26 Global Telomere Gene Therapy Market Outlook, By Aplastic Anemia (2024-2032) ($MN)
  • Table 27 Global Telomere Gene Therapy Market Outlook, By Cancer Subtypes (2024-2032) ($MN)
  • Table 28 Global Telomere Gene Therapy Market Outlook, By Rare Telomere Disorders (2024-2032) ($MN)
  • Table 29 Global Telomere Gene Therapy Market Outlook, By Application (2024-2032) ($MN)
  • Table 30 Global Telomere Gene Therapy Market Outlook, By Anti-Aging & Longevity (2024-2032) ($MN)
  • Table 31 Global Telomere Gene Therapy Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 32 Global Telomere Gene Therapy Market Outlook, By Genetic Disorders (2024-2032) ($MN)
  • Table 33 Global Telomere Gene Therapy Market Outlook, By Regenerative Medicine (2024-2032) ($MN)
  • Table 34 Global Telomere Gene Therapy Market Outlook, By End User (2024-2032) ($MN)
  • Table 35 Global Telomere Gene Therapy Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 36 Global Telomere Gene Therapy Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 37 Global Telomere Gene Therapy Market Outlook, By Biotech & Pharmaceutical Companies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.